Hepatic artery aneurysms (HAAs) are rare, accounting for approximately 14%-20% of visceral artery aneurysms. Most HAAs do not display any symptoms, but they may potentially lead to complications, as in the case of our patient who presented with an HAA compressing the common bile duct, detected through contrast-enhanced endoscopy. There are no specific treatment recommendations for HAAs due to their rarity. However, it is advisable to treat HAAs, even if they are asymptomatic, due to the risk of complications through surgical or radiological means. Our patient was treated with radiological embolization along with endoscopic biliary calibration.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10957008 | PMC |
http://dx.doi.org/10.14309/crj.0000000000001300 | DOI Listing |
Ann Surg Oncol
January 2025
Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Background: A growing number of centers offer hepatic artery infusion pump (HAIP) chemotherapy for advanced liver malignancies. While small series have demonstrated feasibility of robotic HAIP placement, comparison of outcomes with open placement is lacking. We compared outcomes after robotic versus open HAIP placement.
View Article and Find Full Text PDFCureus
December 2024
Medicine, Griffith University, Gold Coast, AUS.
The cystic artery is a critical anatomical landmark in both laparoscopic and open cholecystectomy. This report presents a unique case involving two rare anatomical variations: double cystic arteries, along with a superficial branch originating from the superior mesenteric artery (SMA) - a previously unreported combination with significant clinical and surgical implications. Unlike earlier studies, this research provides detailed anatomical and embryological insights supported by high-quality imaging and illustrations to guide surgeons in recognizing and managing this novel variation.
View Article and Find Full Text PDFFront Immunol
January 2025
The School of Clinical Medicine, Fujian Medical University, Fuzhou, China.
Background: The combination of local therapy with lenvatinib and programmed cell death protein-1 (PD-1) inhibitors represents an emerging treatment paradigm for unresectable hepatocellular carcinoma (uHCC). Our study sought to investigate the interrelationship between gut microbiota and intratumoral microbiota in the context of triple therapy, with a view to identifying potential biological markers.
Methods: The gut microbial community profiles of patients with primary untreated hepatocellular carcinoma (HCC) and those treated with local therapy combined with lenvatinib and PD-1 inhibitors were analyzed by 16S rRNA gene amplicon sequencing.
Front Immunol
January 2025
Department of Radiology, Hubei Key Laboratory of Molecular Imaging, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Background: Infiltrative hepatocellular carcinoma (HCC) remains a therapeutic challenge due to its aggressive course and poor prognosis. Hepatic arterial infusion chemotherapy (HAIC) plus immune checkpoint inhibitors (ICIs) and molecular targeted therapies (MTTs) has shown early promise for advanced HCC, but its role in advanced infiltrative HCC is unclear. This study aims to investigate the efficacy and safety of HAIC combined with ICIs and MTTs in the treatment of advanced infiltrative HCC.
View Article and Find Full Text PDFJ Vasc Bras
January 2025
Universidade Federal do Ceará - UFC, Hospital Universitário Walter Cantídio - HUWC, Fortaleza, CE, Brasil.
Colorectal cancer is one of the most prevalent malignant neoplasms in Brazil. Hepatectomy for resection of liver metastases plays an essential role in increasing disease-free survival, with the possibility of cure. The feasibility of liver resection depends on factors related to the remaining liver after surgery.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!